Ford Hutman Media
Ford Hutman Media provides media relations, thought leadership and executive visibility to health, biotech and digital health companies. The firm was founded by Rachel Ford Hutman, a global health industry connector and creative problem solver. Rachel excels at working with the media to bring health stories to life while making them accessible to stakeholders.
Rachel has worked on some of the world’s biggest therapies and medical technologies of all time, including the first RNAi therapy (Alnylam’s ONPATTRO), the first therapy for Duchenne Muscular Dystrophy (Sarepta’s EXONDYS 51), the first technology in the world to personalize insulin 24 hours a day (Medtronic’s MiniMed 670G) and IBM’s AI launch (Watson). She has counseled some of the most well-known health/ technology organizations and developed communications strategies for the world’s biggest brands (Johnson & Johnson, Medtronic, IBM, Best Buy, Takeda, Sanofi, Shire, Brigham & Women’s, NHS, MIT), and held a senior communications role at IBM.